Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness

Journal of Investigative Dermatology

Volumn 128, Issue 5, 2008, Pages 1182-1191

  Guttman Yassky, Emma ^a   Vugmeyster, Yulia ^b,c   Lowes, Michelle A ^a   Chamian, Francesca ^a   Kikuchi, Toyoko ^a   Kagen, Mark ^a   Gilleaudeau, Patricia ^a   Lee, Edmund ^a   Hunte, Brisdell ^b   Howell, Kathy ^b   Dummer, Wolfgang ^b   Bodary, Sarah C ^b,d   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

^c PFIZER INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; EFALIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 42149156689     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.4     Document Type: Article

References (44)

1. Appleman LJ, Boussiotis VA (2003) T cell anergy and costimulation. Immunol Rev 192:161-80
2. Benjamin RJ, Qin SX, Wise MP, Cobbold SP, Waldmann H (1988) Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol 18:1079-88
3. Bohmig GA, Kovarik J, Holter W, Pohanka E, Zlabinger GJ (1994) Specific downregulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol 152:3720-8
4. Bunting M, Harris ES, McIntyre TM, Prescott SM, Zimmerman GA (2002) Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol 9:30-5
5. Carlos TM, Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood 84:2068-101
6. Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M et al. (2005) Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33:623-9
7. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119:1405-10
8. Ferrara JL, Mauch P, Van Dijken PJ, Crosier KE, Michaelson J, Burakoff SJ (1990) Evidence that anti-asialo GM1 in vivo improves engraftment of T cell-depleted bone marrow in hybrid recipients. Transplantation 49: 134-8
9. Fischer A, Durandy A, Sterkers G, Griscelli C (1986) Role of the LFA-1 molecule in cellular interactions required for antibody production in humans. J Immunol 136:3198-203
10. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62:153-60
11. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M (2002) Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138:591-600
12. Haque S, Dumon H, Haque A, Kasper LH (1998) Alteration of intracellular calcium flux and impairment of nuclear factor-AT translocation in T cells during acute Toxoplasma gondii infection in mice. J Immunol 161:6812-8
13. Hogg N, Bates PA (2000) Genetic analysis of integrin function in man: LAD-1 and other syndromes. Matrix Biol 19:211-22
14. Hogg N, Laschinger M, Giles K, McDowall A (2003) T-cell integrins: more than just sticking points. J Cell Sci 116(Part 23):4695-705
15. Huppa JB, Gleimer M, Sumen C, Davis MM (2003) Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 4:749-55
16. Isobe M, Yagita H, Okumura K, Ihara A (1992) Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255:1125-7
17. Jenkinson SR, Williams NA, Morgan DJ (2005) The role of intercellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. J Immunol 174:3401-7
18. Kanner SB, Grosmaire LS, Ledbetter JA, Damle NK (1993) Beta 2-integrin LFA-1 signaling through phospholipase C-gamma 1 activation. Proc Natl Acad Sci USA 90:7099-103
19. Khanna AK, Hosenpud JD (1999) Cyclosporine induces the expression of the cyclin inhibitor p21. Transplantation 67:1262-8
20. Kinashi T. (2005) Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 5:546-59
21. Krueger JG, Ochs H, Patel P, Gilkerson E, Dummer W (2005) Impact of efalizumab T cell modulation on immune response in psoriasis patients. J Invest Dermatol 124:A44
22. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004-13
23. Lin J, Miller MJ, Shaw AS (2005) The c-SMAC: sorting it all out (or in). J Cell Biol 170:177-82
24. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866-73
25. Lowes MA, Turton JA, Krueger JG, Barnetson RS (2005) Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol 5:9
26. Macian F, Im SH, Garcia-Cozar FJ, Rao A (2004) T-cell anergy. Curr Opin Immunol 16:209-16
27. Meiri KF (2005) Lipid rafts and regulation of the cytoskeleton during T cell activation. Philos Trans R Soc Lond B Biol Sci 360:1663-72
28. Moriyama H, Yokono K, Amano K, Nagata M, Hasegawa Y, Okamoto N et al. (1996) Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol 157:3737-43
29. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB et al. (2005) Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 45:286-98
30. Scheynius A, Camp RL, Pure E (1993) Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. J Immunol 150:655-63
31. Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science 248:1349-56
32. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305-34
33. Shaw JM, Al-Shamkhani A, Boxer LA, Buckley CD, Dodds AW, Klein N et al. (2001) Characterization of four CD18 mutants in leucocyte adhesion deficient (LAD) patients with differential capacities to support expression and function of the CD11/CD18 integrins LFA-1, Mac-1 and p150,95. Clin Exp Immunol 126:311-8
34. Stewart MP, Cabanas C, Hogg N (1996) T cell adhesion to intercellular adhesion molecule-1 (ICAM-1) is controlled by cell spreading and the activation of integrin LFA-1. J Immunol 156:1810-7
35. Szegedi A, Aleksza M, Gonda A, Irinyi B, Sipka S, Hunyadi J et al. (2003) Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol Lett 86:277-80
36. Tanaka Y, Kobayashi K, Takahashi A, Arai I, Higuchi S, Otomo S et al. (1993) Inhibition of inflammatory liver injury by a monoclonal antibody against lymphocyte function-associated antigen-1. J Immunol 151: 5088-95
37. van Kooyk Y, Binnerts ME, Edwards CP, Champe M, Berman PW, Figdor CG et al. (1996) Critical amino acids in the lymphocyte function-associated antigen-1 I domain mediate intercellular adhesion molecule 3 binding and immune function. J Exp Med 183:1247-52
38. Van Seventer GA, Bonvini E, Yamada H, Conti A, Stringfellow S, June CH et al. (1992) Costimulation of T cell receptor/CD3-mediated activation of resting human CD4+ T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels. J Immunol 149:3872-80
39. van Seventer GA, Newman W, Shimizu Y, Nutman TB, Tanaka Y, Horgan KJ et al. (1991) Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med 174:901-13
40. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S (1990) The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144:4579-86
41. Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P et al. (2004) Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113:38-46
42. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T et al. (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157: 4986-95
43. Willenborg DO, Staykova MA, Miyasaka M (1996) Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 157:1973-80
44. Wittkowski KM (2004) Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data. Stat Med 23:2317